AI Summary
→ WHAT IT COVERS Martin Shkreli joins the a16z podcast to analyze the AI model wars between OpenAI and Anthropic, the case for photonic computing as NVIDIA's long-term successor, why peptide biohacking is scientifically unsound, and where pharma entrepreneurs should focus to generate both impact and returns. → KEY INSIGHTS - **OpenAI Revenue Gap:** OpenAI's current enterprise revenue sits around $30B, but Shkreli estimates aggressive monetization matching Anthropic's pricing model could push that figure to roughly $200B. Anthropic charges 5–7x above stated seat prices, billing customers far beyond quoted rates, suggesting significant untapped pricing power exists across the AI platform market. - **Photonic Computing Opportunity:** Light performs matrix multiplications — the core operation in AI workloads — at no energy cost, making optical computing a potential 1,000x to 1,000,000x improvement over silicon in flops-per-watt. Only a handful of startups exist in the space versus thousands of AI agent companies, representing a structurally undercrowded $5–10T hardware opportunity. - **Deep-Domain Software Moats:** Vibe-coding cannot replicate enterprise software requiring 1,800 data relationships, validated bond pricing APIs, and six-month vendor contracts. Traders at firms like Citadel demand accuracy and accountability over convenience. Investors should treat the recent software stock selloff as a buying opportunity in verticals where domain expertise creates durable differentiation. - **Pharma Value Creation Formula:** The highest-return pharma opportunities remain rare diseases and severe cancers, not lifestyle drugs. A single approved therapy for conditions like Duchenne muscular dystrophy can command $1M per patient annually because it restores productivity and eliminates ongoing care costs. Neuralink exemplifies this model — solving paralysis generates insurance-reimbursable value at scale. - **Peptide Biohacking Flaw:** BPC-157, the flagship peptide in self-administration stacks, has a half-life measured in seconds after injection, leaving no pharmacological window to produce therapeutic effects. Drug half-life is a foundational requirement for efficacy. The trend persists because placebo response is real and regulations on unscheduled peptides remain minimal, not because the compounds work. → NOTABLE MOMENT Shkreli argues that SBF's $400M Anthropic investment was a visible red flag at the time — no legitimate individual investor drops that sum in a single deal. He contends the transaction alone should have signaled misappropriated customer funds, and that redemption requires demonstrating genuine human vulnerability, not intellectual combat. 💼 SPONSORS None detected 🏷️ Photonic Computing, AI Monetization, Pharma Drug Development, Peptide Biohacking, OpenAI vs Anthropic
